Jason Meyenburg
Chief Executive Officer at Gemini Therapeutics Sub, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Lubner | M | 60 |
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 4 years |
| Tu Yen Ong | M | 49 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 4 years |
| Jean George | F | 66 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 6 years |
| Philip Reilly | M | - |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | - |
| Carl Gordon | M | 59 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | - |
| Jason Rhodes | M | 54 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | 8 years |
| Bobby Gaspar | M | 60 | 6 years | |
| Hannah Chang | M | - |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | - |
| Leslie Meltzer | M | - | 6 years | |
| Sarah Marshall | F | - | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Georges Gemayel | M | 63 | - | |
| David Brennan | M | 70 | 7 years | |
| David Hallal | M | 56 | 10 years | |
| Joseph A. Madri | M | 80 | 22 years | |
| Mark Rothera | M | 61 | 2 years | |
| Kory Wentworth | M | 45 | 9 years | |
| David W. Keiser | M | 72 | 16 years | |
| Stephen P. Squinto | M | 67 | 23 years | |
| Peter Greenleaf | M | 54 | 4 years | |
| Matthias Alder | M | 59 | 3 years | |
| Maureen O'Connell | F | 62 | 5 years | |
| Charles Rowland | M | 65 | 6 years | |
| Matthew Donley | M | 55 | 4 years | |
| Robert Spiegel | M | 73 | 3 years | |
| Scott Peters | M | - | 8 years | |
| Alexander Pasteur | M | 54 | - | |
| Lisa Lejuwaan | F | - | - | |
| Cristina Csimma | M | 65 |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | 3 years |
| John Curnutte | M | 72 | 5 years | |
| Michael V. Greco | M | 53 | 11 years | |
| Joanne Beck | M | 63 | 6 years | |
| Alicia Secor | F | 62 | 6 years | |
| Brian Piekos | M | 49 | 1 years | |
| John C. King | M | 49 | 9 years | |
| Nicolas Koebel | M | - | - | |
| Jack Mollen | M | 73 | 7 years | |
| Mark Day | M | 52 | 2 years | |
| Alex Driggs | M | 48 | 3 years | |
| Ravichandran Rao | M | - |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | 3 years |
| Jon Ellis | M | 57 | 3 years | |
| Simone Song | F | 59 | - | |
| Felix Baker | M | 55 | 6 years | |
| William Keller | M | 75 | 6 years | |
| Andreas Rummelt | M | 67 | 11 years | |
| John Johnson | M | 66 | 4 years | |
| Elise T. Wang | F | 64 | - | |
| Timothy Walbert | M | 57 | 2 years | |
| James Geraghty | M | 69 | 6 years | |
| Max E. Link | M | 84 | 22 years | |
| Marc Dunoyer | M | 71 | 6 years | |
| M. Burns | F | 66 | 4 years | |
| Francis Wright | M | 76 |
Alexion Pharma GmbH
| 2 years |
| Ann Margaret Veneman | F | 75 | - | |
| Christopher Coughlin | M | 71 | 7 years | |
| Larry L. Mathis | M | 80 | 10 years | |
| Steve Weiss | M | 55 | 4 years | |
| Nancy C. Motola | M | 71 | 10 years | |
| Shane Doyle | M | - | 7 years | |
| Daniel A. Bazarko | M | - | 9 years | |
| Melissa Manno | F | - | 2 years | |
| Massimiliano Colao | M | 59 | 3 years | |
| Vikas Sinha | M | 60 | 11 years | |
| Behrad Derakhshan | M | 44 | 2 years | |
| Rebecca Velez Frey | F | - | 5 years | |
| Brian Krex | M | 57 | 4 years | |
| James Loerop | M | 60 | 2 years | |
| John Tilton | M | 56 | 10 years | |
| Matthew DeLawder | M | - | 5 years | |
| Glenn R. Melrose | M | 68 | - | |
| Thomas-Christian Mix | M | 57 | 2 years | |
| Mohammed Qatanani | M | 50 | 3 years | |
| Micah Zajic | M | 43 | 3 years | |
| George Llado | M | 58 | - | |
| Randy Teel | M | 45 | 2 years | |
| Ted Harding | M | - | 1 years | |
| James Engelhart | M | 60 | 2 years | |
| Kevin Johnson | M | 60 | 1 years | |
| Elena Ridloff | F | 44 | 4 years | |
| Paul W. Finnegan | M | 63 | 6 years | |
| Eric Grinstead | M | 66 | 3 years | |
| Clare M. Carmichael | F | 64 | 6 years | |
| Stephanie Fagan | F | - | 2 years | |
| Paresh N. Soni | M | 63 | 2 years | |
| Heidi Wagner | F | 59 | 9 years | |
| John Moriarty | M | 56 | 6 years | |
| Camille Bedrosian | M | 71 | 10 years | |
| Claus Weisemann | M | - | - | |
| John V. W. Reynders | M | - | 6 years | |
| Joseph Newell | M | 54 | 2 years | |
| Julie O'Neill | F | 58 | 3 years | |
| Romesh R. Subramanian | M | 58 | 3 years | |
| Edward Miller | M | 59 | 3 years | |
| Cheryl Nash | F | - | 4 years | |
| Pritesh Gandhi | M | - | 2 years | |
| Thomas Dubin | M | 62 | 12 years | |
| Christopher F. Mojcik | M | 64 | 9 years | |
| Hyung Bak | M | - | - | |
| Martin MacKay | M | 68 | 4 years | |
| Radhika Tripuraneni | M | 44 | - | |
| Albert Paszek | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 86 | 86.00% |
| United Kingdom | 14 | 14.00% |
| Switzerland | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jason Meyenburg
- Personal Network
